Suoyuan Biosciences introduces global rights of Lingbei's Phase III clinical failure products in Alzheimer's disease

On July 1, U.

In February 2017, two other Alzheimer's (AD) phase III clinical trials of Idalopirdine, STARBEAM and STARBRIGHT, also announced failures

However, in the phase II clinical trial, Idalopirdine performed well.

Idalopirdine is an oral selective 5-HT6 receptor antagonist

Suoyuan Biology published the prospectus on the Science and Technology Innovation Board on June 30, and plans to raise 1.

The advantage of Suoyuan Bio's development of innovative drugs lies in the use of biomarker platform technology to find biomarkers that can predict drug efficacy in residual clinical samples

Currently, the DB102 project of Suoyuan Biosciences is carrying out international multi-center phase III clinical trials for diffuse large B-cell lymphoma (DLBCL) and glioma (GBM)

After the FDA approved the first Aβ monoclonal antibody Aducanumab on June 7, AD drugs became hot again.

The FDA's change of AD drug review standards is the wind direction and inspiration.

Idalopirdine has proven its safety and tolerability in the phase III clinical trials that have been carried out, but the efficacy of the three phase III clinical trials is not satisfactory.